title: A phase II study of Tomudex in relapsed epithelial ovarian cancer.
authors.affiliation: Royal Marsden Hospital, London.
authors.forename: M E
authors.initials: ME
authors.lastname: Gore
authors.forename: H M
authors.initials: HM
authors.lastname: Earl
authors.forename: J
authors.initials: J
authors.lastname: Cassidy
authors.forename: M
authors.initials: M
authors.lastname: Tattersall
authors.forename: J
authors.initials: J
authors.lastname: Mansi
authors.forename: L
authors.initials: L
authors.lastname: Seymour
authors.forename: M
authors.initials: M
authors.lastname: Azab
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D011799:Quinazolines; D013876:Thiophenes; C068874:raltitrexed